C ritical to a successful human immunodeficiency virus (HIV)
program is early HIV diagnosis, linkage to care (LIC), and retention in care (RIC). A previous study in South Carolina found that 41.3% of new HIV diagnoses are tested late in the course of infection. 1 A more recent analysis suggests improvements have been made with a decrease in the proportion of individuals who are tested late in the course of HIV infection to 35% 2 ; however, South Carolina still lags behind other states, ranking 43rd in the percentage of individuals with late HIV diagnosis. 3 Late HIV diagnosis is associated with increased HIVrelated complications, worse health outcomes, shorter life expectancy, and increased HIV transmission, which increase overall health expenditures. 4 Test-and-treat initiatives and guidelines recommending antiretroviral therapy (ART) for all individuals infected with HIV have increased the number of individuals eligible for ART. 4 This means an increased initial cost of care for people infected with HIV. It is, however, anticipated that early diagnosis and treatment would lead to reduced risks of opportunistic infections, reduction in HIV-related morbidity and mortality, and reduced rates of HIV transmission. 4 Although this would be expected to lead to a reduction in the lifetime cost of care (LCC), the economic impact has been difficult to quantify. This study analyzes existing data to determine to what extent an early-versus-late HIV diagnosis would affect LCC in South Carolina.
Methods
The A previously validated simulation model developed by the John Snow Institute for the South Carolina DHEC (Appendices, http://links.lww.com/SMJ/A94 and http://links.lww.com/SMJ/A95) was used to determine discounted (3%) LCC (DLCC) ($US 2013) and quality-adjusted life-years (QALYs). QALY is a generic measure of disease burden used in assessing the financial value of a medical intervention. One QALYequates to 1 year in perfect health. The incremental cost-effectiveness ratio (ICER), a measure of cost-effectiveness based on QALYs saved, also was determined.
The model was developed by reviewing previous studies [5] [6] [7] to identify measures used to determine cost savings for early intervention and LIC. A draft cost analysis model was then developed using Excel software (Microsoft, Redmond, WA) and reviewed by the South Carolina DHEC and their CDC project officer. Further review was conducted by a CDC economist. The model assumed that an intervention is costeffective if the ICER is <$100,000/QALY gained. 
Results

From
Discussion
This analysis demonstrates that the DLCC is higher for individuals infected with HIV diagnosed earlier in their disease course ($416,776 per person) compared with late ($262,374 per person). The results from this analysis are similar to results from a previous study (estimated cost $402,000 with early diagnosis vs $253,000 with late diagnosis and computer simulation model [estimated cost $391,000 with early diagnosis]). 5, 8 It seems paradoxical that late diagnosis is associated with a lower DLCC because late diagnosis is associated with higher rates of opportunistic infections, malignancies, and hospitalizations; however, prior studies have demonstrated that individuals infected with HIV who are diagnosed at later stages have higher initial costs that persist for up to 15 years compared with earlier diagnosis. 9 When the DLCC is considered, however, earlier diagnosis is more costly for several reasons, including a longer time receiving ART, a greater number of clinic follow-up visits, more laboratory costs, and an increased life expectancy associated with extending the time receiving ART. This higher DLCC is offset by an increased life expectancy, fewer lifetime transmissions, and fewer lost QALYs.
The results of this study with regard to lifetime transmission and QALYare in keeping with results from a previous computer simulation. 5, 8 In the present study early diagnosis was associated with an additional 7.4 years life expectancy, which is similar to previous studies that found an increased life expectancy of 7.35 years. 5 Likewise, the present study found a 48.6% reduction in lifetime transmission and 3.5 fewer lost QALYs, identical to that reported by Farnham et al. 5 In addition, the ICER, a measure of the cost-effectiveness of an intervention based on QALYs saved, was found to be favorable (ie, <$100,000). In this study, early and intermediate diagnosis was associated with an ICER of $44,112/QALY gained and $31,947/QALY gained, respectively. This demonstrates that both an early and an intermediate HIV diagnosis are cost-effective when compared with late diagnosis.
If one adds the reduction of secondary infections afforded by early diagnosis, 1331 averted infections with a discounted lifetime cost of $416,776 each, the direct savings attributable to early diagnosis in this cohort would total $554,728,856, which dwarfs the anticipated cost of initiating treatment earlier.
Taken together, these findings provide further support for the benefits of earlier HIV diagnosis and ART initiation, not only in terms of cost-effectiveness but also in fewer lifetime transmissions, increased life expectancy, and fewer lost QALYs.
Our study had several limitations. This was a retrospective analysis based on surveillance data. For the purpose of study analysis, the first CD4s and VLs reported to eHARS were considered to represent the CD4s and VLs at diagnosis and used to categorize study participants into early-, intermediate, and late-diagnosis categories. The first CD4s reported to eHARS may have occurred several months after actual HIV diagnosis, however, in which case certain individuals considered being in the intermediate or late-diagnosis categories actually may represent early diagnosis but late LIC. Early diagnosis/ late LIC would be expected to have an impact on DLCC similar to late diagnosis, however.
Assumptions in the model could change the balance of costeffectiveness. For example, the model assumes a mean age of 35 years at diagnosis. Coincidentally, the median age of infection found in our study also was 35 years. Similarly, in determining the DLCC, the assumption was made that all of the patients had early LIC (ie, within 90 days). Late LIC is associated with lower costs for the same reasons as late diagnosis, as discussed earlier.
Furthermore, LIC is only one aspect of the HIV care continuum and other factors such as RIC and maintenance of virologic suppression would be expected to affect the DLCC, as would QALYs, life expectancy, and lifetime HIV transmissions. One study looking at the HIV cascade of care in South Carolina showed that of 14,523 individuals living with HIV, 64% had received HIV care, 53% were RIC, and 48% were virologically suppressed. 10 
Conclusions
Individuals with an early HIV diagnosis have a higher DLCC, which is more than offset by an increase in additional life expectancy and reduction in lost QALYs and lifetime HIV transmissions. Based on the current findings, interventions to increase early HIV testing, LIC, and RIC in South Carolina will be cost-effective.
